LOGIN  |  REGISTER
Viking Therapeutics

Latest Merger / Acquisition News

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

May 21
Last Trade: 348.46 1.10 0.32

MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is...Read more


Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 21
Last Trade: 7.88 5.57 241.13

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s...Read more


Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21
Last Trade: 9.60 0.00 0.00

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek’s commercial portfolio...Read more


Merit Medical Systems Acquires Biolife Delaware

May 20
Last Trade: 95.11 -1.38 -1.43

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 financial guidance previously...Read more


Regeneron Pharmaceuticals Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

May 19
Last Trade: 596.85 -7.77 -1.29

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases TARRYTOWN, N.Y., May 19, 2025 (GLOBE NEWSWIRE)...Read more


Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

May 19
Last Trade: 5.37 -0.77 -12.54

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five...Read more


BioMarin Pharmaceutical Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16
Last Trade: 58.01 -0.47 -0.80

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m....Read more


Alumis Stockholders Approve Merger with Acelyrin

May 13
Last Trade: 4.84 0.06 1.26

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC....Read more


Acelyrin Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13
Last Trade: 2.27 0.00 0.00

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced,...Read more


Castle Biosciences to Acquire Previse

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire...Read more


electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

May 2
Last Trade: 5.02 0.10 2.03

ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell®...Read more


Resmed Acquires VirtuOx

May 1
Last Trade: 245.49 -0.29 -0.12

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more...Read more


Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

May 1
Last Trade: 0.69 0.02 2.53

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will...Read more


Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

April 30
Last Trade: 6.90 -0.07 -1.00

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired UpLift, an innovative and tech-enabled provider of virtual mental health therapy, psychiatry and medication management services.    The acquisition supports the company’s strategy to further enhance its leadership position in virtual mental health, including the ability for consumers served...Read more


U.S. Physical Therapy Announces the Acquisition of an Outpatient Home Care Physical and Speech Therapy Practice

April 30
Last Trade: 75.40 -1.88 -2.43

HOUSTON / Apr 30, 2025 / Business Wire / U.S. Physical Therapy, Inc. (the Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of an outpatient home care practice that provides physical, occupational, and speech therapy through its 50%-owned subsidiary, MSO Metro, LLC (“Metro”). The practice currently generates approximately $2.1...Read more


Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

April 30
Last Trade: 7.91 -0.01 -0.13

Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO, April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company...Read more


Quanterix and Akoya Biosciences Announce Amended Merger Agreement

April 29
Last Trade: 4.85 0.04 0.83

Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. & MARLBOROUGH, Mass. / Apr 29, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger...Read more


Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement

April 29
Last Trade: 3.84 0.06 1.59

FREEHOLD, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, and YOOV Group Holding Limited (“YOOV”), a provider of highly advanced artificial intelligence (“AI”) automation solutions, jointly announced the filing with the U.S. Securities and Exchange Commission (“SEC”) of a...Read more


Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

April 28
Last Trade: 77.84 0.86 1.12

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion)  Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business  SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults...Read more


LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market

April 28
Last Trade: 11.50 0.73 6.78

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide women’s health virtual care provider. This strategic acquisition marks LifeMD’s official entry into the women’s health market and establishes a scalable clinical foundation for a comprehensive virtual health...Read more


Medicus Pharma Announces a Binding Letter of Intent to Acquire Antev for ~US$75 Million in a Share Exchange Transaction

April 28
Last Trade: 5.69 0.00 0.00

Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate Cancer Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based late...Read more


Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

April 23
Last Trade: 0.69 -0.05 -6.49

Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng...Read more


Jazz Pharmaceuticals Completes Acquisition of Chimerix

April 21
Last Trade: 107.82 -0.45 -0.42

Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned...Read more


Alumis and ACELYRIN Announce Amended Merger Agreement

April 21
Last Trade: 4.84 0.06 1.26

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files...Read more


Ligand Pharmaceuticals Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

April 17
Last Trade: 101.29 -1.16 -1.13

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI...Read more


Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

April 16
Last Trade: 36.34 -0.11 -0.30

Bruker and RECIPE are pioneering the high-throughput ‘chrom-free’ ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays MUNICH / Apr 16, 2025 / Business Wire / Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and...Read more


GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

April 16
Last Trade: 67.33 -0.45 -0.66

Combining GeneDx’s industry-leading rare disease data asset and Fabric Genomics’ AI-powered platform furthers the Company’s leadership and creates an unrivaled platform to deliver global access to genomic information Accelerates the NICU, enables newborn screening, and opens global market opportunities with on-site sequencing and decentralized interpretation GAITHERSBURG, Md. & OAKLAND, Calif. / Apr 16, 2025 / Business Wire /...Read more


Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

April 16
Last Trade: 2.05 -0.03 -1.44

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep...Read more


RadNet to Acquire iCAD to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

April 15
Last Trade: 56.77 -1.29 -2.22

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the...Read more


Longevity Health Announces Execution of Merger Agreement With 20/20 Biolabs

April 14
Last Trade: 0.20 0.00 0.00

PITTSBURGH, Pa. & GAITHERSBURG, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a merger agreement (the “Merger”) with 20/20 BioLabs,...Read more


Medicure Announces Further Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of West Olympia Pharmacy

April 11
Last Trade: 0.94 0.00 0.00

WINNIPEG, MB / ACCESS Newswire / April 11, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it has signed a definitive agreement on April 10, 2025 to acquire 100% of...Read more


VitalHub Announces Recommended Cash Acquisition of Induction Healthcare

April 10
Last Trade: 10.42 0.13 1.26

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: VHIBF) is pleased to announce that it has agreed the terms and conditions of a recommended cash acquisition to acquire all of the issued and to be issued share capital of Induction Healthcare Group PLC (“Induction”) by way of a court-sanctioned scheme of arrangement (the “Acquisition”) under Part 26 of the Companies Act 2006. Under...Read more


Wellgistics Health Announces Agreement to Acquire Peek Healthcare Technologies, to Support Over 2,500 Patients and $1.5MM Annual Revenue

TAMPA, FL / ACCESS Newswire / April 10, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced it has entered into a definitive agreement to acquire Peek Healthcare Technologies, Inc. ("Peek"). Peek operates the Peek Meds Marketplace, a digital...Read more


Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with...Read more


BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

April 7
Last Trade: 22.10 0.01 0.05

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy...Read more


Aveanna Healthcare Announces Agreement to Acquire Thrive Skilled Pediatric Care

April 3
Last Trade: 5.35 -0.14 -2.55

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it has entered into an agreement to acquire Thrive Skilled Pediatric Care ("Thrive SPC"). The transaction is expected to close in the second fiscal quarter of 2025, subject to customary regulatory...Read more


Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

April 2
Last Trade: 152.61 -0.57 -0.37

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care...Read more


CareCloud Acquires RevNu Medical Management, Completing Second Acquisition in 31 Days

SOMERSET, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of practice management, healthcare technology and AI-driven solutions to medical practices across the country, today announced the acquisition of RevNu Medical Management (“RevNu”), an emerging audiology-focused revenue cycle management (“RCM”) company based in Westminster, California. “We’ve spent years...Read more


Allakos Enters into Agreement to Be Acquired by Concentra Biosciences for $0.33 in Cash per Share

April 2
Last Trade: 0.33 0.00 0.00

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0.33 in cash per share of Allakos common stock...Read more


HEALWELL AI Completes Acquisition of Orion Health, Becoming a Global Leader in Healthcare Data Interoperability and Artificial Intelligence

HEALWELL has acquired Auckland, New Zealand-based Orion Health Holdings Limited ("Orion Health"), a global healthcare intelligence platform providing subscription licenses and services to marquee public sector clients with data interoperability and healthcare navigation products. Orion Health1 has approximately 400 employees with offices in 11 countries globally. Its software solutions currently support over 70 public and private...Read more


Qualigen Therapeutics seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

April 1
Last Trade: 3.79 0.03 0.66

CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of full due...Read more


GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will...Read more


HOPE Therapeutics and NRx Pharmaceuticals Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

March 31
Last Trade: 2.69 0.06 2.28

Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Operations for HOPE in Florida MIAMI,...Read more


Scinai Immunotherapeutics signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

March 27
Last Trade: 2.83 -0.03 -1.06

Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's Agency An application will be filed with the FDA for Orphan Drug and Breakthrough Designation...Read more


Alcon Acquires Majority Interest in Aurion Biotech to Advance Innovative Cell Therapy for Corneal Endothelial Disease

March 26
Last Trade: 86.14 -1.40 -1.60

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy...Read more


MindBio Therapeutics Acquires Life AI

March 26
Last Trade: 0.01 0.00 0.00

Vancouver, British Columbia – TheNewswire - March 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing, is pleased to announce the completion of its acquisition of all of the outstanding share capital of Life AI Corp. Pty. Ltd. (“Life AI”) pursuant to a definitive share purchase agreement (the “SPA”) dated effective...Read more


Shineco Announces Acquisition of Medical Device Company

March 25
Last Trade: 0.69 -0.05 -6.49

The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of the...Read more


Alcon Agrees to Acquire LENSAR

March 24
Last Trade: 13.98 0.00 0.00

Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology...Read more


HOPE Therapeutics and NRx Pharmaceuticals Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings for Expansion of its Planned International Network of Interventional Psychiatry Clinics

March 24
Last Trade: 2.69 0.06 2.28

Neurospa currently operates six interventional psychiatry clinics on Florida's Gulf Coast HOPE to acquire majority interest in Neurospa for a combination of cash and equity Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions Acquisition to be accretive to HOPE revenue projections...Read more


MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

March 24
Last Trade: 1.23 0.02 1.65

Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. MIAMI, FL / ACCESS Newswire / March 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA"), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, announced today that it has signed a binding...Read more


Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length...Read more


Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

March 20
Last Trade: 9.94 -0.22 -2.17

REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in...Read more


Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

March 20
Last Trade: 2.03 0.63 45.00

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN)...Read more


Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18
Last Trade: 0.04 -0.06 -57.00

SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would...Read more


EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

March 17
Last Trade: 69.95 0.27 0.39

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more...Read more


Tempus Announces Acquisition of Deep 6 AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO / Mar 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare...Read more


Knight Therapeutics to Acquire Paladin

March 11
Last Trade: 5.76 0.00 0.00

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin Pharma Inc., to acquire the Paladin business (“Paladin”). At closing, Knight will pay an upfront payment of $120 million in cash, including inventory with...Read more


NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

March 10
Last Trade: 7.28 -0.12 -1.62

FT. MYERS, Fla. / Mar 10, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and...Read more


2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

March 10
Last Trade: 4.99 0.00 0.00

$5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions CAMBRIDGE, Mass. / Mar 10, 2025 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total...Read more


Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

March 10
Last Trade: 3.84 0.06 1.59

YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023 Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV” FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Avalon...Read more


Sun Pharmaceutical to Acquire Checkpoint Therapeutics

March 9
Last Trade: 4.17 -0.005 -0.12

Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence to accelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock, representing aggregate upfront consideration of up to $355...Read more


Walgreens Boots Alliance Enters into Definitive Agreement to Be Acquired by Sycamore Partners

Total Consideration Consists of $11.45 per Share in Cash and Additional Potential Value of Up To $3.00 in Cash per WBA Share from Future Monetization of VillageMD Businesses Sycamore and WBA Combine Retail and Healthcare Expertise to Better Position WBA to Accelerate Turnaround Plan DEERFIELD, Ill. & NEW YORK / Mar 06, 2025 / Business Wire / Walgreens Boots Alliance (NASDAQ: WBA) (the "Company" or “WBA”) today announced that it...Read more


Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 5
Last Trade: 8.54 0.00 0.00

Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors Transaction to add near-term commercial opportunity to Jazz's pipeline Transaction represents total cash consideration of approximately $935 million, or $8.55 per share DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX)...Read more


TC Biopharm Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

March 5
Last Trade: 0.50 0.00 0.00

FDA-approved product in a multi-billion-dollar market Revenue generation projected in 2025 EDINBURGH, Scotland, March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a...Read more


Boston Scientific announces agreement to acquire SoniVie

March 3
Last Trade: 104.50 -0.14 -0.13

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An...Read more


U.S. Physical Therapy Announces the Acquisition of a Three-Clinic Physical Therapy Practice

March 3
Last Trade: 75.40 -1.88 -2.43

HOUSTON / Mar 03, 2025 / Business Wire / U.S. Physical Therapy, Inc. (the Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of a physical therapy practice with three clinic locations in Wyoming, which currently generates approximately $4.3 million in annual revenues and 23,000 in annual visits. The Company acquired a 65%...Read more


Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

March 3
Last Trade: 0.03 0.00 0.00

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- TORONTO, March 3, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025,...Read more


Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

February 27
Last Trade: 26.07 -0.07 -0.27

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization  Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with disease-modifying potential for prevalent musculoskeletal diseases with significant unmet needs  Brings preclinical portfolio and research and development talent  Provides expected near-term and long-term financial benefits with...Read more


Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

February 26
Last Trade: 0.33 0.04 15.15

Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an...Read more


Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

February 25
Last Trade: 2.04 0.00 0.00

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314. “This is a significant milestone for our efforts to advance...Read more


bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

February 21
Last Trade: 4.99 0.02 0.40

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions bluebird’s Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives Carlyle and SK Capital, in collaboration with a team of highly experienced biotech...Read more


Acelyrin Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

February 20
Last Trade: 2.27 0.00 0.00

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00...Read more


Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy

February 18
Last Trade: 0.94 0.00 0.00

WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it has signed a definitive agreement on February 14, 2025 to acquire 100% of...Read more


PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...Read more


NanoVibronix Announces Acquisition of ENvue Medical Holdings

February 14
Last Trade: 1.08 -0.10 -8.47

ELMSFORD, N.Y. / Feb 14, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. (“ENvue”) (the “Acquisition”), a privately-held, innovative leader in enteral feeding solutions. This strategic transaction will combine the strengths of both companies, creating a...Read more


Bio-Rad Laboratories Offers to Acquire Digital PCR Developer Stilla Technologies

February 13
Last Trade: 227.14 -0.84 -0.37

Transaction To Complement Bio-Rad’s Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions HERCULES, Calif. / Feb 13, 2025 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies...Read more


CareSpan Health Enters Into Definitive Agreement With Medtech AI And Concurrent Financing

VANCOUVER, BC, Feb. 13, 2025 /CNW/ - CareSpan Health, Inc. (TSXV: CSPN) (the "Company" or "CareSpan"), announces that it has entered into a binding definitive agreement among Medtech AI Inc. ("Medtech"), a company incorporated under the laws of Ontario, and 1001132953 Ontario Inc., a company existing under the laws of Ontario, (the "SubCo") effective as of February 11, 2025 (the "Definitive Agreement"), whereby CareSpan will acquire...Read more


Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

February 11
Last Trade: 112.50 -0.28 -0.25

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation Acquisition adds a late-stage asset and is aligned with Novartis strategic focus, strength and expertise in...Read more


HEALWELL AI Receives Regulatory Approval from Overseas Investment Office of New Zealand to Acquire Orion Health

February 10
Last Trade: 1.40 0.02 1.45

HEALWELL receives consent from the Overseas Investment Office of New Zealand (the "OIO") for HEALWELL to acquire all of the shares (the "Orion Shares") of Orion Health Holdings Limited ("Orion Health"), as contemplated in the previously disclosed share purchase agreement dated December 16, 2024. Orion Health is a leader in global healthcare technology, with over 70 customers worldwide in 11 countries and approximately 400 team...Read more


DocGo Acquires PTI Health To Expand Proactive Healthcare Offering with Mobile Lab Collection and Mobile Phlebotomy Services

February 10
Last Trade: 1.34 0.06 4.69

NEW YORK / Feb 10, 2025 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced the acquisition of PTI Health, a mid-Atlantic mobile lab collection and phlebotomy services company. This strategic move expands DocGo’s healthcare service offering to include mobile phlebotomy lab services, addressing critical gaps in diagnostic care for underserved...Read more


Crown Laboratories Completes Acquisition of Revance Therapeutics

February 7
Last Trade: 3.65 0.00 0.00

NEW YORK / Feb 07, 2025 / Business Wire / Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. Jeff Bedard, Founder...Read more


Globus Medical to Acquire Nevro to Expand Treatment Options for Patients

February 6
Last Trade: 58.60 -0.68 -1.15

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction....Read more


Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

February 6
Last Trade: 4.84 0.06 1.26

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December...Read more


Teladoc Health to Acquire Catapult Health, Advancing Integrated Care Strategy

February 5
Last Trade: 6.90 -0.07 -1.00

PURCHASE, NY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that it has signed a definitive agreement to acquire Catapult Health, a leading provider of virtual preventive care services. The company plans to leverage Catapult Health’s innovative approach to patient-centric at-home diagnostic testing, as well as its high-touch engagement and clinical support model, to...Read more


McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings

February 4
Last Trade: 710.64 -8.09 -1.13

Acquisition enhances McKesson’s capabilities as a national partner in retina and ophthalmology care IRVING, Texas / Feb 04, 2025 / Business Wire / McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services, from Quad-C. McKesson will purchase an 80%...Read more


BioNTech Completes Acquisition of Biotheus

February 3
Last Trade: 99.07 -0.02 -0.02

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local...Read more


Molina Healthcare Announces the Closing of its Acquisition of ConnectiCare

February 3
Last Trade: 309.77 -9.85 -3.08

LONG BEACH, Calif. / Feb 03, 2025 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced that its acquisition of ConnectiCare Holding Company, Inc. (“ConnectiCare”) closed effective as of February 1, 2025. At closing, ConnectiCare served approximately 140,000 members across Marketplace, Medicare, and certain commercial products. About Molina Healthcare Molina Healthcare, Inc., a FORTUNE 500 company, provides managed...Read more


Tempus AI Completes Acquisition of Ambry Genetics

February 3
Last Trade: 59.36 1.22 2.10

CHICAGO / Feb 03, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. “This acquisition complements our strategy of leveraging diagnostics and...Read more


Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

January 31
Last Trade: 1.95 0.23 13.37

ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for...Read more


Telix Pharmaceuticals Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

January 30
Last Trade: 16.20 -0.46 -2.76

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE